Trial Profile
A study evaluating retention rate and efficacy of adalimumab as second biologic agent in etanercept (ETN) non-responder Rheumatoid Arthritis and Psoriatic Arthritis Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2017
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept
- Indications Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- 01 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism